Anyone following this? Looks like a hostile takeover strategy case study. It covers staggered boards, proxy advisory firms, and poison pills. Really interesting. Is it gonna happen? If you were the adviser to Roche or Illumina, what would tell them?
Out of curiosity, how are hedgies and arbs playing this?
| +264 | UBS Layoffs (October 2026) | 79 | 27m |
| +120 | Do people still want to go PE? | 36 | 4h |
| +95 | UBS Tech layoff | 31 | 1h |
| +36 | Lazard hirevue | 11 | 1d |
| +36 | What Differentiates the Best Analysts as AI Improves? | 9 | 1d |
| +31 | How do YOU manage networking requests? | 5 | 28m |
| +25 | Cornell Club T10 Rankings (UPDATED 10/2026) | 16 | 30m |
| +24 | Quitting After First 4 months | 10 | 23h |
| +20 | MBB Pay Raises | 10 | 26m |
| +18 | Are target prospects getting dumber? | 11 | 1h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Well Roche rescinded their bid, so it's over. Illumina won.
http://dealbook.nytimes.com/2012/04/18/illumina-fends-off-roches-hostil…
[quote=SECfinance]Well Roche rescinded their bid, so it's over. Illumina won.
http://dealbook.nytimes.com/2012/04/18/illumina-fends-off-roches-hostil…]
Look at their previous 2 major acquisitions. Both Ventana and Genentech took more than 6 months to buy. Do you really think it's over?
I think it's over for now. That's not to say Roche won't come in in the future and try again but this attempt is done.
Tempore quam saepe optio eos aut. Harum rerum odio eos id saepe quaerat atque. Corporis a non sunt quibusdam omnis aspernatur suscipit enim.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...